drug
hydroxyurea
Marketedupdated 6mo agoby Nova Laboratories Ltd
Approvedcommunity read0 votes
indications
investigational
Sickle Cell Disease
all catalysts(0)
nothing on the calendar yet
Trials studying hydroxyurea
- phase2Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
- phase3Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa
- —Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera
- phase3Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
- phase4Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
- —Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- phase1A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
- phase1A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 4, 2027
137 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Dec 23, 2041formulationUS 12409156
FDA exclusivities (2)
- Apr 4, 2031ODE-470Orphan Drug (7y)4.4y
- Apr 4, 2027NPNP137d
News(5)
- Beam’s base editing therapy for sickle cell hits goal in pivotal trialThe result represents a scientific milestone and positions Beam to submit a first-of-its-kind FDA application as soon as the end of the year.biopharma_dive · 7d ago
- Alethio raises $90M to target rare blood cancersThe startup is working on a medicine one of its investors claimed could have a broader reach than other approved drugs for a group of conditions known as myeloproliferative neoplasms.biopharma_dive · 13d ago
- Merck KGaA bets on RNAi with $1.3B Silence buyoutThe acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.biopharma_dive · 29d ago
- FDA OKs Takeda, Protagonist drug for rare blood cancerThe clearance and broader-than-expected label for Mimrylo open up a yearly revenue opportunity for Takeda that some analysts expect to reach $2 billion or more.biopharma_dive · 2mo ago
- Second Clinical Scenario - Progressive Disease Despite Hematocrit ControlPolycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that